Roivant reports Phase 2 win for lung disease drug that it got from Bayer

Roivant lung disease drug meets Phase 2 goals, shares surge 20%

Roivant Sciences reported its experimental inhaled drug for interstitial lung disease met primary endpoints in a mid-stage trial for pulmonary hypertension, with shares rising about 20% on the news.